Over recent weeks, new treatments for people with non small cell lung cancer have been authorised for use by the NHS, raising expectations of longer survival and a reduced risk of the cancer returning.
According to Cancer Research UK, the use of an immunotherapy drug, pembrolizumab, in combination with chemotherapy drugs, is now to be made available through the NHS for people with untreated squamous non small cell lung cancer. Trials showed that this combination could increase life expectancy in patients whose cancer has already spread to other parts of the bodyp.
Another immunotherapy drug, atezolizumab, is also to be made available in England for use in the treatment of lung cancer. Its use is appropriate for people with early-stage non small cell lung cancer who have undergone surgery and chemotherapy. Trials have shown that it can reduce the chance of the cancer returning. It is already used in the treatment of other cancer types.
In other news, the BBC has reported that Cancer Research UK is planning to award £100 million to seven cancer research centres across the UK over the next five years. It is to support the work of research into earlier diagnosis of a wide range of cancers.
Medical negligence legal advice
If you or a loved one are struggling with the consequences of delayed diagnosis and treatment of cancer, contact Glynns Solicitors, specialists in medical negligence compensation law.
Please call us on 0800 234 3300 (or from a mobile 01275 334030) or complete our Online Enquiry Form.
Share Article With:
|
|
|
|
|
|
